Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
AbstractPurpose of ReviewApolipoprotein C-III (apoC-III) is known to inhibit lipoprotein lipase (LPL) and function as an important regulator of triglyceride metabolism. In addition, apoC-III has also more recently been identified as an important risk factor for cardiovascular disease. This review summarizes the mechanisms by which apoC-III induces hypertriglyceridemia and promotes atherogenesis, as well as the findings from recent clinical trials using novel strategies for lowering apoC-III.Recent FindingsGenetic studies have identified subjects with heterozygote loss-of-function (LOF) mutations in APOC3, the gene coding for apoC-III. Clinical characterization of these individuals shows that the LOF variants associate with a low-risk lipoprotein profile, in particular reduced plasma triglycerides. Recent results also show that complete deficiency of apoC-III is not a lethal mutation and is associated with very rapid lipolysis of plasma triglyceride-rich lipoproteins (TRL). Ongoing trials based on emerging gene-silencing technologies show that intervention markedly lowers apoC-III levels and, consequently, plasma triglyceride. Unexpectedly, the evidence points to apoC-III not only inhibiting LPL activity but also suppressing removal of TRLs by LPL-independent pathways.SummaryAvailable data clearly show that apoC-III is an important cardiovascular risk factor and that lifelong deficiency of apoC-III is cardioprotective. Novel therapies have been developed, and results from rece...
At least 22 people have developed some type of respiratory illness after vaping or using e-cigarettes
HIGH blood pressure is a common condition in the UK. Making certain lifestyle tweaks can help to lower a soaring reading. According to a recent study, a popular juice may also do the trick.
Review of "Atlas of Artifacts in Clinical Neurophysiology," by William O. Tatum, IV Atlas of Artifacts in Clinical Neurophysiology by William O. Tatum , IV, Demos Medical Publishing, 2018 , 419 pages. ISBN: 9780826169341 . E-book ISBN: 978-0826169358 . List Price: $185.00; Amazon New: $154.02; Amazon Used: $144.00; Kindle: $129.36. Neurodiagn J. 2019 Aug 23;:1-2 Authors: Clark-Bash RJ PMID: 31441708 [PubMed - as supplied by publisher]
Authors: Moosavian SP, Arab A, Mehrabani S, Moradi S, Nasirian M Abstract Background: Several studies have investigated the effect of omega-3 fatty acids and vitamin E on oxidative stress and inflammation, but their findings are inconsistent. The aim of this meta-analysis is to elucidate the overall effects of co-supplementation with omega-3 fatty acids and vitamin E on oxidative stress and inflammation. Methods: We searched titles, abstracts, and keywords of relevant articles indexed in PubMed, ISI, Scopus, and Google Scholar databases up to December 2018 to identify eligible RCT studies. Random effects model was...
Conclusion: These results provide a potential mechanism involving AMPK activation/ROS inhibition signaling pathway in osteogenic differentiation of BMSCs enhanced by resveratrol. It suggests that development of therapy towards ROS is an effective way for osteoporosis treatment. PMID: 31438780 [PubMed - in process]